Dr. Kittai Discusses Richter Transformation in CLL: Unmet Needs, Novel Therapies
By Adam Kittai, MD, Melissa Badamo, Patrick Daly - Last Updated: October 9, 2024Adam Kittai, MD, of the Icahn School of Medicine at Mount Sinai, joins Blood Cancers Today at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas, to discuss Richter transformation in chronic lymphocytic leukemia (CLL).
Advertisement
Dr. Kittai described three trials evaluating novel therapies for Richter transformation:
- Pirtobrutinib
- Zanabrutinib plus tislelizumab
- Chimeric antigen receptor T-cell (CAR-T) therapy
“There’s encouraging data out there using our new medications for Richter transformation, but we still have a lot of work to do to figure out how best to treat these patients,” Dr. Kittai said.
Advertisement
Related Posts
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.